PMID- 18339074
OWN - NLM
STAT- MEDLINE
DCOM- 20080512
LR  - 20181201
IS  - 1478-3231 (Electronic)
IS  - 1478-3223 (Linking)
VI  - 28
IP  - 4
DP  - 2008 Apr
TI  - Comparing the safety, tolerability and quality of life in patients with chronic 
      hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a.
PG  - 477-85
LID - 10.1111/j.1478-3231.2008.01696.x [doi]
AB  - BACKGROUND/AIMS: Hepatitis B and C viruses (HBV and HCV) are two clinically 
      distinct but related diseases. Pooled data from five studies of peginterferon 
      alpha-2a in patients with chronic HCV infection (CHC) were compared with two 
      studies of the drug in patients with chronic HBV infection (CHB). METHOD: The HBV 
      studies included both hepatitis B e antigen (HBeAg)-positive (n=271) and 
      HBeAg-negative (n=177) patients; 791 patients took part in the HCV trials. In all 
      studies, patients were treated with 180 microg peginterferon alpha-2a monotherapy 
      once weekly for 48 weeks. The number of adverse events (AEs), discontinuations 
      and dose modifications were documented. Health-related quality of life (HRQL) was 
      assessed using the Short-Form 36 questionnaire. Safety was assessed throughout 
      the treatment period. A 24-week treatment-free follow-up period was also 
      included. RESULTS: Differences (HBV vs HCV) were observed in the incidence of AEs 
      (88-89 vs 96-100%), serious AEs (4-5 vs 7-16%) and treatment withdrawals (6-8 vs 
      17-33%). The frequency of depression-related events was lower in CHB patients (4 
      vs 22%, P<0.001), as was the impact of treatment on HRQL. CONCLUSIONS: The safety 
      and tolerability of peginterferon alpha-2a in patients with CHB compares 
      favourably with that observed in CHC patients, with a lower incidence of common 
      interferon-related AEs and a significantly lower incidence of depression.
FAU - Marcellin, Patrick
AU  - Marcellin P
AD  - Service d'Hepatologie & INSERM CRB3, University of Paris, Hopital Beaujon, 
      Clichy, France. patrick.marcellin@bjn.ap-hop-paris.fr
FAU - Lau, George K K
AU  - Lau GK
FAU - Zeuzem, Stefan
AU  - Zeuzem S
FAU - Heathcote, E Jenny
AU  - Heathcote EJ
FAU - Pockros, Paul J
AU  - Pockros PJ
FAU - Reddy, K Rajender
AU  - Reddy KR
FAU - Piratvisuth, Teerha
AU  - Piratvisuth T
FAU - Farci, Patrizia
AU  - Farci P
FAU - Chow, Wan-Cheng
AU  - Chow WC
FAU - Jia, Ji-Dong
AU  - Jia JD
FAU - Paik, Woon
AU  - Paik W
FAU - Wintfeld, Neil
AU  - Wintfeld N
FAU - Pluck, Nigel
AU  - Pluck N
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Liver Int
JT  - Liver international : official journal of the International Association for the 
      Study of the Liver
JID - 101160857
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (Recombinant Proteins)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - Q46947FE7K (peginterferon alfa-2a)
SB  - IM
CIN - Liver Int. 2008 Apr;28(4):429-31. PMID: 18339069
MH  - Adult
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug-Related Side Effects and Adverse Reactions
MH  - Female
MH  - Hepatitis B, Chronic/diagnosis/*drug therapy/mortality
MH  - Hepatitis C, Chronic/diagnosis/*drug therapy/mortality
MH  - Humans
MH  - Interferon alpha-2
MH  - Interferon-alpha/*administration & dosage/adverse effects
MH  - Liver Function Tests
MH  - Male
MH  - Maximum Tolerated Dose
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Polyethylene Glycols/*administration & dosage/adverse effects
MH  - Probability
MH  - Prognosis
MH  - *Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Recombinant Proteins
MH  - Reference Values
MH  - Risk Assessment
MH  - Severity of Illness Index
MH  - Survival Rate
MH  - Treatment Outcome
EDAT- 2008/03/15 09:00
MHDA- 2008/05/13 09:00
CRDT- 2008/03/15 09:00
PHST- 2008/03/15 09:00 [pubmed]
PHST- 2008/05/13 09:00 [medline]
PHST- 2008/03/15 09:00 [entrez]
AID - LIV1696 [pii]
AID - 10.1111/j.1478-3231.2008.01696.x [doi]
PST - ppublish
SO  - Liver Int. 2008 Apr;28(4):477-85. doi: 10.1111/j.1478-3231.2008.01696.x.